Overview
RESTORE tests whether Augmented-FLS, where patients are contacted by a patient navigator (serving as the liaison) and referred to a bone health provider, is better than Enhanced Usual Care, which includes patient and PCP education and activation. We also aim to determine the influence of age, race, ethnicity, sex, poverty level, geographic region, and timing of entry into the trial after a fracture on the effectiveness of the two strategies.
Eligibility
Inclusion Criteria:
- Age 50 years and older (no upper age limit)
- Sustained a primary fragility fracture (hip/femur/pelvis, clinical spine, humerus, wrist/forearm) in the last 6 months
- Participant must self-identify a regular primary care provider (PCP)
Exclusion Criteria:
- Exposure to the following medications in the prior 12 months
- Actonel or Atelvia (risedronate)
- Fosamax or Binosto (alendronate)
- Reclast, Zometa, or Aclasta (zoledronic acid, zoledronate)
- Boniva or Bondronat (ibandronate)
- Aredia (pamidronate)
- Prolia (denosumab)
- Evenity (romozosumab)
- Tymlos (abaloparatide)
- Forteo (teriparatide)
- Natpara (parathyroid hormone)
- Evista (raloxifene)
- Miacalcin (calcitonin)
- Diagnosis of the following medical conditions
- CKD stage 4 and above
- Paget's disease
- Multiple myeloma
- Osteomalacia
- Addison's disease
- Adrenal insufficiency
- Enrolled hospice care
- Solid organ transplant
- Bone marrow transplant
- Fractures resulting from severe trauma
- Scheduled appointment with a bone health clinician